We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Marking a big step in its march toward potential approval, GlaxoSmithKline’s shingles vaccine Shingrix won the support of an FDA panel as experts touted its strengths over Merck’s Zostavax.